Form 4: Serina Therapeutics CSO Sells Shares After Option Exercise

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 2,500 shares of common stock under a Rule 10b5-1 plan.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc., engaged in an insider transaction on January 22, 2026.
• The transaction involved the exercise of 2,500 stock options at an exercise price of $0.06 per share.
• Immediately following the exercise, 2,500 shares of common stock were sold at a price of $2.95 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan, indicating they were pre-arranged.
• Following these transactions, the reporting person's direct beneficial ownership of common stock from these specific transactions is 0 shares, while 326,186 stock options remain beneficially owned.

Sentiment

Score: 5

Explanation: Neutral. While an insider sale can be seen as slightly negative, this appears to be a routine exercise and sale under a pre-planned 10b5-1 program, likely for liquidity or tax purposes, rather than a signal of lack of confidence in the company's future.

Positives

• The exercise of options indicates the executive is realizing value from previously granted equity compensation.
• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, suggesting it was not based on new, non-public information.

Negatives

• An officer selling shares, even if pre-planned, can sometimes be perceived negatively by the market as it reduces their direct equity stake.

Future Outlook

NA

Industry Context

This is a routine insider transaction for an executive exercising stock options and selling shares, common across all industries, particularly in biotechnology where equity compensation is prevalent. It does not provide specific insights into broader industry trends.

Stakeholder Impact

• Shareholders: Minor impact. A small reduction in direct insider ownership, but the transaction was pre-planned.
• Employees: No direct impact.
• Customers/Suppliers/Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the Chief Scientific Officer exercised vested stock options and sold the resulting shares under a Rule 10b5-1 plan. Such transactions are common for executive compensation and liquidity management and typically do not signal a fundamental change in the company's prospects or warrant a change in investment recommendation based solely on this filing. The relatively small number of shares sold suggests minimal market impact.

Keywords

Serina Therapeutics, SER, Randall Moreadith, Chief Scientific Officer, Insider Trading, Form 4, Stock Options, Equity Sale, Rule 10b5-1